Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Oct 16 - Oct 21
Combining AHK-Cu with GHK-Cu targets multiple copper peptide pathways simultaneously
It targets stubborn fat stores that remain resistant to diet and exercise alone, reigniting progress
This multi-receptor approach distinguishes it from existing licensed medicines such as semaglutide (Ozempic, Wegovy) or tirzepatide licensed in the UK as Mounjaro for type 2 diabetes and as Zepbound for obesity which act on fewer receptor pathways
Timeline for visible results The earliest noticeable changes typically appear around the two to three month mark
Regular measurement of hematologic parameters is recommended in all patients on chronic metformin treatment
US$ 29.69
US$ 24.27
US$ 20.85
US$ 23.80
